| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Cardiovascular Research Institute and Department of Anatomy, University of California, San Francisco, CA 94143; and
Chiron Vaccines, Emeryville, CA 94608
Intramuscular injection of DNA vaccines elicits potent humoral and cellular immune responses in mice. However, DNA vaccines are less efficient in larger animal models and humans. To gain a better understanding of the factors limiting the efficacy of DNA vaccines, we used fluorescence-labeled plasmid DNA in mice to 1) define the macroscopic and microscopic distribution of DNA after injection into the tibialis anterior muscle, 2) characterize cellular uptake and expression of DNA in muscle and draining lymph nodes, and 3) determine the effect of modifying DNA distribution and cellular uptake by volume changes or electroporation on the magnitude of the immune response. Injection of a standard 50-µl dose resulted in the rapid dispersion of labeled DNA throughout the muscle. DNA was internalized within 5 min by muscle cells near the injection site and over several hours by cells that were located along muscle fibers and in the draining lymph nodes. Histochemical staining and analysis of mRNA expression in isolated cells by RT-PCR showed that the transgene was detectably expressed only by muscle cells, despite substantial DNA uptake by non-muscle cells. Reduction of the injection volume to 5 µl resulted in substantially less uptake and expression of DNA by muscle cells, and correspondingly lower immune responses against the transgene product. However, expression and immunogenicity were restored when the 5-µl injection was followed by electroporation in vivo. These findings indicate that distribution and cellular uptake significantly affect the immunogenicity of DNA vaccines.
This article has been cited by other articles:
|
|
 |
|
  H. Shirota, L. Petrenko, C. Hong, and D. M. Klinman Potential of Transfected Muscle Cells to Contribute to DNA Vaccine Immunogenicity J. Immunol., July 1, 2007; 179(1): 329 - 336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Mwangi, W. C. Brown, G. A. Splitter, C. J. Davies, C. J. Howard, J. C. Hope, Y. Aida, Y. Zhuang, B. J. Hunter, and G. H. Palmer DNA Vaccine Construct Incorporating Intercellular Trafficking and Intracellular Targeting Motifs Effectively Primes and Induces Memory B- and T-Cell Responses in Outbred Animals Clin. Vaccine Immunol., March 1, 2007; 14(3): 304 - 311. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Mwangi, W. C. Brown, G. A. Splitter, Y. Zhuang, K. Kegerreis, and G. H. Palmer Enhancement of antigen acquisition by dendritic cells and MHC class II-restricted epitope presentation to CD4+ T cells using VP22 DNA vaccine vectors that promote intercellular spreading following initial transfection J. Leukoc. Biol., August 1, 2005; 78(2): 401 - 411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Donnelly, B. Wahren, and M. A. Liu DNA Vaccines: Progress and Challenges J. Immunol., July 15, 2005; 175(2): 633 - 639. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. R. Otten, M. Schaefer, B. Doe, H. Liu, I. Srivastava, J. zur Megede, J. Kazzaz, Y. Lian, M. Singh, M. Ugozzoli, et al. Enhanced Potency of Plasmid DNA Microparticle Human Immunodeficiency Virus Vaccines in Rhesus Macaques by Using a Priming-Boosting Regimen with Recombinant Proteins J. Virol., July 1, 2005; 79(13): 8189 - 8200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Buchan, E. Gronevik, I. Mathiesen, C. A. King, F. K. Stevenson, and J. Rice Electroporation as a "Prime/Boost" Strategy for Naked DNA Vaccination against a Tumor Antigen J. Immunol., May 15, 2005; 174(10): 6292 - 6298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. K. Stevenson, C. H. Ottensmeier, P. Johnson, D. Zhu, S. L. Buchan, K. J. McCann, J. S. Roddick, A. T. King, F. McNicholl, N. Savelyeva, et al. DNA vaccines to attack cancer PNAS, October 5, 2004; 101(suppl_2): 14646 - 14652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Munoz-Montesino, E. Andrews, R. Rivers, A. Gonzalez-Smith, G. Moraga-Cid, H. Folch, S. Cespedes, and A. A. Onate Intraspleen Delivery of a DNA Vaccine Coding for Superoxide Dismutase (SOD) of Brucella abortus Induces SOD-Specific CD4+ and CD8+ T Cells Infect. Immun., April 1, 2004; 72(4): 2081 - 2087. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. V. E. Capozzo, V. P. Creydt, G. Dran, G. Fernandez, S. Gomez, L. V. Bentancor, C. Rubel, C. Ibarra, M. Isturiz, and M. S. Palermo Development of DNA Vaccines against Hemolytic-Uremic Syndrome in a Murine Model Infect. Immun., July 1, 2003; 71(7): 3971 - 3978. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. V. Rao, P. F. Watson, A. P. Weetman, G. Carayanniotis, and J. P. Banga Contrasting Activities of Thyrotropin Receptor Antibodies in Experimental Models of Graves' Disease Induced by Injection of Transfected Fibroblasts or Deoxyribonucleic Acid Vaccination Endocrinology, January 1, 2003; 144(1): 260 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Rice, S. Buchan, and F. K. Stevenson Critical Components of a DNA Fusion Vaccine Able to Induce Protective Cytotoxic T Cells Against a Single Epitope of a Tumor Antigen J. Immunol., October 1, 2002; 169(7): 3908 - 3913. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Al-Mariri, A. Tibor, P. Mertens, X. De Bolle, P. Michel, J. Godfroid, K. Walravens, and J.-J. Letesson Induction of Immune Response in BALB/c Mice with a DNA Vaccine Encoding Bacterioferritin or P39 of Brucella spp. Infect. Immun., October 1, 2001; 69(10): 6264 - 6270. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. O'Hagan, M. Singh, M. Ugozzoli, C. Wild, S. Barnett, M. Chen, M. Schaefer, B. Doe, G. R. Otten, and J. B. Ulmer Induction of Potent Immune Responses by Cationic Microparticles with Adsorbed Human Immunodeficiency Virus DNA Vaccines J. Virol., October 1, 2001; 75(19): 9037 - 9043. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Rice, T. Elliott, S. Buchan, and F. K. Stevenson DNA Fusion Vaccine Designed to Induce Cytotoxic T Cell Responses Against Defined Peptide Motifs: Implications for Cancer Vaccines J. Immunol., August 1, 2001; 167(3): 1558 - 1565. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
